Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sigurdur Gretarsson, Alexander Nygren, Ann H. Rosendahl, Nektaria Mylona, Elisabeth Kjellén, Yuesheng Jin, Kajsa Paulsson, Åke Borg, Eva Brun, Jan Tennvall, Anders Bergenfelz, Lennart Greiff, Johan Wennerberg & Lars Ekblad. (2020) Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines. Acta Oto-Laryngologica 140:4, pages 337-343.
Read now
Read now
Silvia Martina Ferrari, Poupak Fallahi, Concettina La Motta, Giusy Elia, Francesca Ragusa, Ilaria Ruffilli, Armando Patrizio, Enke Baldini, Salvatore Ulisse & Alessandro Antonelli. (2019) Recent advances in precision medicine for the treatment of anaplastic thyroid cancer. Expert Review of Precision Medicine and Drug Development 4:1, pages 37-49.
Read now
Read now
Poupak Fallahi, Ilaria Ruffilli, Giusy Elia, Francesca Ragusa, Salvatore Ulisse, Enke Baldini, Mario Miccoli, Gabriele Materazzi, Alessandro Antonelli & Silvia Martina Ferrari. (2017) Novel treatment options for anaplastic thyroid cancer. Expert Review of Endocrinology & Metabolism 12:4, pages 279-288.
Read now
Read now
Articles from other publishers (34)
Viswanath GundaChandrayee Ghosh, Jiangnan HuLisa ZhangYa qin ZhangMin ShenElectron Kebebew. (2023)
Combination
BRAF
V600E
Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in
BRAF
V600E
-Mutant Anaplastic Thyroid Cancer
. Thyroid® 33:10, pages 1201-1214.
Crossref
Crossref
Marianna Aprile, Simona Cataldi, Caterina Perfetto, Antonio Federico, Alfredo Ciccodicola & Valerio Costa. (2023) Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype. British Journal of Cancer 129:2, pages 249-265.
Crossref
Crossref
Xiaoni Gao, Chengcheng Hong, Yang Xie & Xiangtai Zeng. (2023) Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?. Frontiers in Oncology 13.
Crossref
Crossref
P. A. Isaev, V. V. Polkin, N. V. Severskaya, A. A. Ilyin, A. K. Plugar, S. A. Ivanov & A. D. Kaprin. (2023) Results of treatment of patients with poorly differentiated carcinoma of the thyroid gland. Head and Neck Tumors (HNT) 12:4, pages 17-24.
Crossref
Crossref
Matthias Lang, Thomas Longerich & Chrysanthi Anamaterou. (2023) Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer. Thyroid Research 16:1.
Crossref
Crossref
Christiane Jungels, Jaime Miguel Pita & Giuseppe Costante. (2023) Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy. Current Opinion in Oncology 35:1, pages 1-9.
Crossref
Crossref
Sabine Wächter, Sebastian Hoffmann & Andreas Zielke. 2023. Endokrine Chirurgie. Endokrine Chirurgie
189
207
.
Alireza Heidari, Sophia Iorgulescu, Olivia Robinson, Lin Hu, Charlotte Vauclin, Ntalie Schiltz, Scarlett Sondermann, Lucy MacLennan, Julia Smith, Lydia Williamson, Alireza Heidari, Sophia Iorgulescu, Olivia Robinson, Lin Hu, Charlotte Vauclin, Ntalie Ntalie Schiltz, Scarlett Sondermann, Lucy MacLennan, Julia Smith, Lydia Williamson, Alireza Heidari, Sophia Iorgulescu, Olivia Robinson, Lydia Williamson, Lin Hu, Charlotte Vauclin, Ntalie Schiltz, Scarlett Sondermann, Lucy MacLennan, Julia Smith, Alireza Heidari & Zahra Torfeh. (2022) CERN Large Hadron Collider (LHC) Radiation Source for Magnetic Resonance Biospectroscopy in Metabolic and Molecular Imaging and Diagnosis of Cancer. Journal of New Developments in Chemistry 3:4, pages 29-30.
Crossref
Crossref
Camille Buffet, Lucie Allard, Erell Guillerm, Cécile Ghander, Elise Mathy, Charlotte Lussey-Lepoutre, Nicolas Julien, Eliane Touma, Pauline Quilhot, Gaelle Godiris-Petit, Jean-Marc Lacorte, Laurence Leenhardt & Jérôme Alexandre Denis. (2022) Detection of BRAFV600E by digital PCR on fine-needle aspirate enables rapid initiation of dabrafenib and trametinib in unresectable anaplastic thyroid carcinoma. European Journal of Endocrinology 187:3, pages K33-K38.
Crossref
Crossref
Jacob J. Adashek, Arjun K. Menta, Neha K. Reddy, Aakash P. Desai, Jason Roszik & Vivek Subbiah. (2022) Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors. Molecular Cancer Therapeutics 21:6, pages 871-878.
Crossref
Crossref
守博 李. (2022) Current Status of Targeted Therapy for Undifferentiated Thyroid Cancer. Advances in Clinical Medicine 12:02, pages 804-809.
Crossref
Crossref
Ayesha Munir & Irina G. Veytsman. 2022. A Case-Based Guide to Clinical Endocrinology. A Case-Based Guide to Clinical Endocrinology
129
140
.
Shivam Patel, Dana Goldenberg & Darrin V. Bann. (2021) The role of surgery in the management of anaplastic thyroid carcinoma. Operative Techniques in Otolaryngology-Head and Neck Surgery 32:2, pages e27-e31.
Crossref
Crossref
Keith C. BibleElectron KebebewJames BrierleyJuan P. BritoMaria E. CabanillasThomas J. ClarkJr.Jr., Antonio Di CristofanoRobert FooteThomas GiordanoJan KasperbauerKate NewboldYuri E. NikiforovGregory RandolphM. Sara RosenthalAnna M. SawkaManisha ShahAshok ShahaRobert SmallridgeCarol K. Wong-Clark. (2021) 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid 31:3, pages 337-386.
Crossref
Crossref
Sabine Wächter, Sebastian Hoffmann & Andreas Zielke. 2021. Viszeral- und Allgemeinchirurgie. Viszeral- und Allgemeinchirurgie
1
19
.
Simone De Leo, Matteo Trevisan & Laura Fugazzola. (2020) Recent advances in the management of anaplastic thyroid cancer. Thyroid Research 13:1.
Crossref
Crossref
Shichen Xu, Xian Cheng, Liying Wu, Jiangxia Zheng, Xiaowen Wang, Jing Wu, Huixin Yu, Jiandong Bao & Li Zhang. (2020) Capsaicin induces mitochondrial dysfunction and apoptosis in anaplastic thyroid carcinoma cells via TRPV1-mediated mitochondrial calcium overload. Cellular Signalling 75, pages 109733.
Crossref
Crossref
María San Román Gil, Javier Pozas, Javier Molina-Cerrillo, Joaquín Gómez, Héctor Pian, Miguel Pozas, Alfredo Carrato, Enrique Grande & Teresa Alonso-Gordoa. (2020) Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy. International Journal of Molecular Sciences 21:14, pages 4951.
Crossref
Crossref
Joana Simões-Pereira, Ricardo Capitão, Edward Limbert & Valeriano Leite. (2019) Anaplastic Thyroid Cancer: Clinical Picture of the Last Two Decades at a Single Oncology Referral Centre and Novel Therapeutic Options. Cancers 11:8, pages 1188.
Crossref
Crossref
Zongjuan Li, Yang Zhang, Ruonan Wang, Kun Zou & Lijuan Zou. (2019) Genetic alterations in anaplastic thyroid carcinoma and targeted therapies (Review). Experimental and Therapeutic Medicine.
Crossref
Crossref
Josip Ljubas, Therese Ovesen & Maria Rusan. (2019) A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer. Cancers 11:7, pages 943.
Crossref
Crossref
Kelsey L. Corrigan, Hannah Williamson, Danielle Elliott Range, Donna Niedzwiecki, David M. Brizel & Yvonne M. Mowery. (2019) Treatment Outcomes in Anaplastic Thyroid Cancer. Journal of Thyroid Research 2019, pages 1-11.
Crossref
Crossref
Ethan J. Harris, Glenn J. Hanna, Nicole Chau, Guilherme Rabinowits, Robert Haddad, Danielle N. Margalit, Jonathan Schoenfeld, Roy B. Tishler, Justine A. Barletta, Matthew Nehs, Pasi Janne, Julian Huang, Phillip Groden, Alec Kacew & Jochen Lorch. (2019) Everolimus in Anaplastic Thyroid Cancer: A Case Series. Frontiers in Oncology 9.
Crossref
Crossref
M Rashid, Amit Agarwal, Roma Pradhan, Nelson George, Niraj Kumari, M Sabaretnam, Gyan Chand, Anjali Mishra, Gaurav Agarwal & SarojKanta Mishra. (2019) Genetic alterations in anaplastic thyroid carcinoma. Indian Journal of Endocrinology and Metabolism 23:4, pages 480.
Crossref
Crossref
Jeffrey A. Knauf, Kathleen A. Luckett, Kuen-Yuan Chen, Francesca Voza, Nicholas D. Socci, Ronald Ghossein & James A. Fagin. (2018) Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. Journal of Clinical Investigation 128:9, pages 4086-4097.
Crossref
Crossref
Vera Tiedje, Martin Stuschke, Frank Weber, Henning Dralle, Laura Moss & Dagmar Führer. (2018) Anaplastic thyroid carcinoma: review of treatment protocols. Endocrine-Related Cancer 25:3, pages R153-R161.
Crossref
Crossref
Robert C. Smallridge, John D. Casler & Michael E. Menefee. 2018. Practical Management of Thyroid Cancer. Practical Management of Thyroid Cancer
297
305
.
Matthias A. Roelli, Dorothée Ruffieux-Daidié, Amandine Stooss, Oussama ElMokh, Wayne A. Phillips, Matthias S. Dettmer & Roch-Philippe Charles. (2017) PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors. Oncotarget 8:61, pages 103207-103222.
Crossref
Crossref
Shweta Kotian, Lisa Zhang, Myriem Boufraqech, Kelli Gaskins, Sudheer Kumar Gara, Martha Quezado, Naris Nilubol & Electron Kebebew. (2017) Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases. Clinical Cancer Research 23:17, pages 5044-5054.
Crossref
Crossref
Eleonora Molinaro, Cristina Romei, Agnese Biagini, Elena Sabini, Laura Agate, Salvatore Mazzeo, Gabriele Materazzi, Stefano Sellari-Franceschini, Alessandro Ribechini, Liborio Torregrossa, Fulvio Basolo, Paolo Vitti & Rossella Elisei. (2017) Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nature Reviews Endocrinology 13:11, pages 644-660.
Crossref
Crossref
Vera Tiedje, Saskia Ting, Thomas Herold, Sarah Synoracki, Soeren Latteyer, Lars C. Moeller, Denise Zwanziger, Martin Stuschke, Dagmar Fuehrer & Kurt Werner Schmid. (2017) NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma. Oncotarget 8:26, pages 42613-42620.
Crossref
Crossref
Benjamin BonhommeYann GodbertGaelle PerotAbir Al GhuzlanStéphane BardetGeneviève BelleannéeLise CrinièreChristine Do CaoGeneviève FouillouxSerge GuyetantAntony KellySophie LeboulleuxCamille BuffetEmmanuelle LeteurtreJean-Jacques MichelsFrédérique TissierMarie-Elisabeth ToubertMichel WassefClémence PinardIsabelle HosteinIsabelle Soubeyran. (2017) Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases. Thyroid 27:5, pages 682-692.
Crossref
Crossref
Claire F. Verschraegen, Hibba Rehman, Bhargavi Pulluri, James DeKay, Maura Barry, Edmund Folefac, Kim Dittus, Chris Holmes, Julian Sprague, Steve Ades & Pam C. Gibson. (2017) When Clinical Trial Participation Is Not an Option in the Era of Personalized Medicine: The Case of Two Patients. Oncology 92:1, pages 55-60.
Crossref
Crossref
Svetlana A. Protsenko, Anna I. Semionova, Yuri I. Komarov, Svetlana N. Aleksakhina, Alexandr O. Ivantsov, Aglaya G. Iyevleva & Evgeny N. Imyanitov. (2015) BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. Investigational New Drugs 33:5, pages 1136-1143.
Crossref
Crossref